Fennec Pharmaceuticals Ord Shs T.FRX

Alternate Symbol(s): FENC

Healthcare Biotechnology

Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on its product candidate PEDMARK. It sells its product through a field force, including Regional Pediatric Oncology Specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is a Food and Drug Administration approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. It is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase 3 clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6. It has established Fennec HEARS, a single source program designed to connect PEDMARK patients.

TSX:FRX - Post by User

Fennec Pharmaceuticals Ord Shs

Bullboard Posts

Post by Brinkleyon Jun 06, 2016 7:12am

298 Views

Post# 24936732

Discussion of results?

I would love to hear opinions from others following the company for a while.

From the Cog trial we saw that the drug protected hearing, STS was much more effective in the young patient population.

is that enough to go to the regulators for drug approval? Do we need to wait for the final efficacy results for Siopel next year?

I feel as though a lot of the risk in the stock just got removed. It's just a matter of time now.

Thoughts?

Bullboard Posts

Debt-free cannabis company set for next stage of growth